Abstract #4723

Early MR-detectable biomarkers of mutant IDH inhibition in patient-derived low-grade gliomas in vivo

Marina Radoul¹, Chloé Najac¹, Donghyun Hong¹, Anne Marie Gillespie¹, Pavithra Viswanath¹, Russell O. Pieper^2,3, Joseph F. Costello², and Sabrina M. Ronen^1,3

¹Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, United States, ²Neurological Surgery, University of California San Francisco, San Francisco, CA, United States, ³Brain Tumor Research Center, University of California San Francisco, San Francisco, CA, United States

Low-grade glioma (LLG) patients have a relatively long-term survival of ~13 years but these tumors always recur. Since IDH mutations are present in >80% of LGGs, inhibition of mutant IDH activity is being tested as a new therapeutic approach. Here, we investigated response to mutant IDH inhibition by AG-881 in orthotopic LGG mouse models. Using in vivo ¹H MRS we detected, in addition to a decrease in 2-HG, an early increase in both glutamate and glutamine/glutamate that were associated with subsequent tumor shrinkage. This identifies potential early metabolic biomarkers of LGG response to mutant IDH inhibition.

This abstract and the presentation materials are available to members only; a login is required.

Join Here